Results 171 to 180 of about 856,952 (362)
Role of 3′,5′-cyclic AMP in the control of nuclear protein kinase activity [PDF]
, 1973 Lora E. Rikans, Raymond W. Ruddoh
openalex +1 more source
Emerging role of ARHGAP29 in melanoma cell phenotype switching
Molecular Oncology, EarlyView.This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster +3 more
wiley +1 more source
The (2′‐5′)Oligoadenylate (pppA2′‐5′A2′‐5′A) Synthetase and Protein Kinase(s) from Interferon‐Treated Cells [PDF]
, 1979 Ara G. Hovanessian, Ian M. Kerr
openalex +1 more source
Molecular Oncology, EarlyView.Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf +10 more
wiley +1 more source
Cyclic Nucleotide‐Independent Protein Kinases from Rabbit Reticulocytes [PDF]
, 1979 Polygena T. Tuazon +2 more
openalex +1 more source
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source
Protein Kinase Modulator from Lobster Tail Muscle
, 1973 Thomas E. Donnelly +4 more
openalex +1 more source